Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4473 - The prognostic value of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status in left- and right-sided metastatic colorectal cancer (mCRC): a Belgian population-based study.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy;  Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Katleen Janssens

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

K. Janssens1, G. van Camp2, K. Op de Beeck3, E. Fransen4, F. Calay5, N. van Damme5, M. Peeters6

Author affiliations

  • 1 Internal Medicine, University of Antwerp, 2000 - Antwerp/BE
  • 2 Medical Genetics, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
  • 3 Center Of Oncological Research (core), University of Antwerp, Edegem/BE
  • 4 Statua, University of Antwerp, 2650 - Edegem/BE
  • 5 Belgian Cancer Registry, Belgian cancer registry, 1210 - Sint-Joost-ten-Node/BE
  • 6 Medical Oncology, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4473

Background

In recent years, various studies have convincingly shown that mCRC patients with left-sided primaries have a significantly better prognosis than those with right-sided tumors. More research is required to identify the biomarkers that cause this difference in survival. Furthermore, these conclusions are mostly based on data of clinical trials and therefore selected patients. Confirmation in population-based studies is necessary. Therefore, the aim of current study is to compare the impact of biomarkers on survival rates in left- and right-sided mCRC in the (non-selected) Belgian population.

Methods

In Belgium, data on patient and tumor characteristics of all new diagnosed cancers are collected in the Belgian Cancer Registry. A random sample of 1035 patients diagnosed with mCRC in 2014 was included in our analysis. We obtained information on age, sex, primary tumor location, biomarker data (MMR status and BRAF, KRAS and NRAS mutational status) and survival. We constructed a logistic regression model, using location, age, gender and biomarkers as independent variables and survival as dependent variable.

Results

After exclusion of 177 patients with a second tumor, the study included 858 mCRC patients: 268 (31.24%) with right-sided mCRC, 352 (41.03%) with left-sided mCRC, 212 (24.71%) with rectal cancer and 26 (2.03%) with an overlapping lesion or unknown localization. KRAS and BRAF mutations were more frequently observed in right-sided tumors compared to left-sided tumors, whereas NRAS mutations were more frequently observed in left-sided CRC compared to right-sided CRC. Microsatellite instability (MSI)-high tumors were more frequently observed on the right side of the colon. Detailed overall survival data according to tumor location and biomarker status will be available at the congress.

Conclusions

We present the survival data of 1035 Belgian mCRC patients according to age, sex, tumor location and biomarker status. Currently, we can conclude that in Belgian patients left-sided mCRC has a better prognosis than right-sided mCRC, regardless of biomarkers status.

Clinical trial identification

Legal entity responsible for the study

University of Antwerp.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.